- Home
- SPGI vs AMGN Comparison
SPGI vs AMGN Comparison
Compare SPGI & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPGI
- AMGN
- Stock Information
- Founded
- SPGI 1860
- AMGN 1980
- Country
- SPGI United States
- AMGN United States
- Employees
- SPGI N/A
- AMGN N/A
- Industry
- SPGI Finance: Consumer Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPGI Finance
- AMGN Health Care
- Exchange
- SPGI Nasdaq
- AMGN Nasdaq
- Market Cap
- SPGI 150.8B
- AMGN 141.6B
- IPO Year
- SPGI N/A
- AMGN N/A
- Fundamental
- Price
- SPGI $501.92
- AMGN $272.11
- Analyst Decision
- SPGI Buy
- AMGN Buy
- Analyst Count
- SPGI 15
- AMGN 22
- Target Price
- SPGI $583.62
- AMGN $324.05
- AVG Volume (30 Days)
- SPGI 1.3M
- AMGN 3.5M
- Earning Date
- SPGI 02-11-2025
- AMGN 02-04-2025
- Dividend Yield
- SPGI 0.73%
- AMGN 3.50%
- EPS Growth
- SPGI 46.60
- AMGN N/A
- EPS
- SPGI 11.32
- AMGN 7.83
- Revenue
- SPGI $13,768,000,000.00
- AMGN $32,534,000,000.00
- Revenue This Year
- SPGI $14.75
- AMGN $20.07
- Revenue Next Year
- SPGI $6.46
- AMGN $3.59
- P/E Ratio
- SPGI $44.34
- AMGN $34.74
- Revenue Growth
- SPGI 12.10
- AMGN 21.25
- 52 Week Low
- SPGI $407.69
- AMGN $253.30
- 52 Week High
- SPGI $533.29
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- SPGI 52.76
- AMGN 54.19
- Support Level
- SPGI $478.60
- AMGN $267.15
- Resistance Level
- SPGI $503.27
- AMGN $272.82
- Average True Range (ATR)
- SPGI 7.61
- AMGN 4.68
- MACD
- SPGI 1.20
- AMGN 2.37
- Stochastic Oscillator
- SPGI 81.70
- AMGN 75.60
About SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.